Invossa Emerging Drug Insight and Market Forecast - 2032

This “Invossa Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about invossa for osteoarthritis in the six major markets. A detailed picture of the invossa for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada for the study period 2019 -2032 is provided in this report along with a detailed description of the invossa for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the invossa market forecast analysis for osteoarthritis in the 6MM, along with Canada, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.

Drug Summary

Invossa (TG-C) is an allogeneic (donor) cell and gene therapy involving primary human chondrocytes (cartilage cells) and human cells transduced to express the therapeutic growth factor TGF-ß1. Invossa (TG-C) is a combination of the two. It has been developed to treat knee OA and is delivered via one intra-articular injection into the knee.

A first-in-class cell-mediated gene therapy, TG-C LD targets knee OA through a single intra-articular injection. Kolon TissueGene, the license holder for TG-C in the United States (not TG-C LD), has completed a Phase II clinical trial in the United States, with initial data demonstrating sustained pain relief and mobility improvement following a single injection in the knee joint, for possibly up to 2 years. Phase III clinical trials in the United States comprising 1,020 patients are currently ongoing to confirm the safety and efficacy of TG-C. In addition, to confirm the statistically significant pain reduction and function improvements observed from the US Phase II clinical trial, the trials are designed to show the delay of disease progression to achieve a DMOAD (Disease Modifying Osteoarthritis Drug) designation.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the invossa description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.
• Elaborated details on invossa regulatory milestones and other development activities have been provided in this report.
• The report also highlights the invossa research and development activities in osteoarthritis across the United States, Europe and Canada.
• The report also covers the patents information with expiry timeline around invossa.
• The report contains forecasted sales of invossa for osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.
• The report also features the SWOT analysis with analyst views for invossa in osteoarthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Invossa Analytical Perspective

In-depth Invossa Market Assessment

This report provides a detailed market assessment of invossa for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada. This segment of the report provides forecasted sales data from 2024 to 2032.

Invossa Clinical Assessment

The report provides the clinical trials information of invossa for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence invossa dominance.
• Other emerging products for osteoarthritis are expected to give tough market competition to invossa and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of invossa in osteoarthritis.
• This in-depth analysis of the forecasted sales data of invossa from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the invossa in osteoarthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of invossa?
• What is the clinical trial status of the study related to invossa in osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the invossa development?
• What are the key designations that have been granted to invossa for osteoarthritis?
• What is the forecasted market scenario of invossa for osteoarthritis?
• What are the forecasted sales of invossa in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada?
• What are the other emerging products available and how are these giving competition to invossa for osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?

This product will be delivered within 2 business days.